{
    "name": "filgrastim",
    "comment": "Rx",
    "other_names": [
        "G-CSF",
        "Neupogen",
        "tbo-filgrastim",
        "Granix",
        "Zarxio",
        "filgrastim-sndz",
        "Nivestym",
        "filgrastim-aafi",
        "Releuko",
        "filgrastim-ayow"
    ],
    "classes": [
        "Hematopoietic Growth Factors"
    ],
    "source": "https://reference.medscape.com/drug/g-csf-neupogen-filgrastim-342164",
    "pregnancy": {
        "common": [
            "Available data from published studies, including several observational studies of pregnancy outcomes in women exposed to filgrastim products and those who were unexposed, have not established an association with use during pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes",
            "Reports in scientific literature have described transplacental passage of drug in pregnant women when administered less than or equal to 30 hours prior to preterm delivery (less than or equal to 30 weeks' gestation)",
            "In animal reproduction studies, effects of filgrastim on prenatal development have been studied in rats and rabbits; no malformations were observed in either species; no maternal or fetal effects were observed in pregnant rats at doses up to 58 times the human doses; drug has been shown to have adverse effects in pregnant rabbits at doses 2 -10 times higher than the human doses"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There is published literature documenting transfer of filgrastim into human milk; there are a few case reports describing use of filgrastim in breastfeeding mothers with no adverse effects noted in the infants; there are no data on effects of filgrastim on milk production; other filgrastim products are secreted poorly into breast milk, and filgrastim products are not absorbed orally by neonates; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on the breastfed child from the drug or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "History of serious allergic reactions to filgrastim or pegfilgrastim products"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Allergic reactions reported (angioneurotic edema, dermatitis-allergic, hypersensitivity, rash, pruritic rash, and urticaria); allergic reactions can recur within days after discontinuation of initial antiallergic treatment; permanently discontinue therapy in patients with serious allergic reactions",
                "Associated with rare cases of potentially fatal splenic rupture; evaluate if patient experiences left upper abdominal and/or shoulder tip pain",
                "Rare cases of ARDS reported; evaluate patients who develop fever and lung infiltrates or respiratory distress for ARDS; discontinue therapy in patients with ARDS",
                "Monitor for thrombocytopenia",
                "Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders; discontinue therapy if sickle cell crisis occurs",
                "Glomerulonephritis reported; if suspected, evaluate for cause; if causality likely, consider dose-reduction or interruption",
                "Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone-imaging changes; this should be considered when interpreting bone-imaging results",
                "WBC counts ≥100‚000/mm³ were observed in ~2% of patients receiving filgrastim at dosages >5 mcg/kg/day",
                "Off-label use for PBPC mobilization has resulted in alveolar hemorrhage, resulting in pulmonary infiltrates and hemoptysis",
                "Cutaneous vasculitis has been reported; hold therapy in patients with cutaneous vasculitis; therapy may be started at a reduced dose when the symptoms resolve and the ANC has decreased",
                "Capillary leak syndrome (CLS) can occur in patients receiving filgrastim products and is characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration; patients who develop symptoms of CLS should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care",
                "In patients with cancer receiving the drug as an adjunct to myelosuppressive chemotherapy‚ to avoid the potential risks of excessive leukocytosis‚ recommended that therapy be discontinued if the ANC surpasses 10‚000/mm³ after the chemotherapy-induced ANC nadir has occurred; monitor CBC counts at least twice weekly during therapy; dosages that increase the ANC beyond 10‚000/mm³ may not result in any additional clinical benefit",
                "During period of administration of therapy for PBPC mobilization in patients with cancer, discontinue therapy if leukocyte count rises to >10‚000/mm³",
                "Simultaneous use with chemotherapy and radiation therapy not recommended",
                "Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone-imaging changes; consider when interpreting bone-imaging results",
                "Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes; this should be considered when interpreting bone-imaging results"
            ],
            "specific": [
                {
                    "type": "Aortitis",
                    "description": [
                        "Aortitis has been reported; may occur as early as the first week after start of therapy",
                        "Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (eg, C-reactive protein and WBC)",
                        "Consider aortitis in patients who develop these signs and symptoms without known etiology",
                        "Discontinue if aortitis is suspected"
                    ]
                },
                {
                    "type": "Severe chronic neutropenia",
                    "description": [
                        "Confirm if patients have severe chronic neutropenia (SCN)",
                        "Myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) have been reported to occur in the natural history of congenital neutropenia without cytokine therapy",
                        "MDS and AML reported in patients with breast and lung cancer receiving chemotherapy and/or radiotherapy; monitor patients for signs and symptoms of MDS/AML in these settings",
                        "Effect of filgrastim on the development of abnormal cytogenetics and the effect of continued administration in patients with abnormal cytogenetics or MDS are unknown",
                        "If a patient with SCN develops abnormal cytogenetics or myelodysplasia‚ the risks and benefits should be carefully considered before continuing treatment"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Drugs that may potentiate the release of neutrophils‚ such as lithium‚ should be used with caution",
                        "Safety and efficacy of concomitantly using filgrastim with cytotoxic chemotherapy or radiation therapy have not been established; because of the potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy‚ do not use in the period 24 hr before through 24 hr after the administration of cytotoxic chemotherapy"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Nausea",
            "percent": "57"
        },
        {
            "name": "Vomiting",
            "percent": "57"
        },
        {
            "name": "Bone pain",
            "percent": "22"
        },
        {
            "name": "Alopecia",
            "percent": "33"
        },
        {
            "name": "Diarrhea",
            "percent": "18"
        },
        {
            "name": "Fever",
            "percent": "14"
        },
        {
            "name": "Fatigue",
            "percent": "12"
        },
        {
            "name": "Headache",
            "percent": "11"
        },
        {
            "name": "Anorexia",
            "percent": null
        },
        {
            "name": "Chest pain",
            "percent": null
        },
        {
            "name": "Cough",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "Constipation",
            "percent": null
        },
        {
            "name": "Stomatitis",
            "percent": null
        },
        {
            "name": "Sore throat",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Elevated uric acid",
            "percent": null
        },
        {
            "name": "Elevated lactate dehydrogenase",
            "percent": null
        },
        {
            "name": "Elevated alkaline phosphatase",
            "percent": null
        },
        {
            "name": "Splenic rupture",
            "percent": null
        },
        {
            "name": "ARDS",
            "percent": null
        },
        {
            "name": "Asthenia",
            "percent": null
        },
        {
            "name": "Glomerulonephritis",
            "percent": null
        },
        {
            "name": "Alveolar hemorrhage and hemoptysis",
            "percent": null
        },
        {
            "name": "Sickle cell crisis",
            "percent": null
        },
        {
            "name": "Cutaneous vasculitis",
            "percent": null
        },
        {
            "name": "Sweet syndrome",
            "percent": null
        },
        {
            "name": "acute febrile neutrophilic dermatosis",
            "percent": null
        },
        {
            "name": "Decreased bone density and osteoporosis in children with severe chronic neutropenia receiving long",
            "percent": null
        },
        {
            "name": "term treatment",
            "percent": null
        },
        {
            "name": "Aortitis",
            "percent": null
        },
        {
            "name": "Respiratory distress syndrome",
            "percent": null
        },
        {
            "name": "Myelodysplastic syndrome",
            "percent": null
        },
        {
            "name": "Acute myeloid leukemia",
            "percent": null
        },
        {
            "name": "Capillary leak syndrome",
            "percent": null
        },
        {
            "name": "Extramedullary hematopoiesis",
            "percent": null
        }
    ]
}